Welcome to our dedicated page for Petros Pharmaceuticals news (Ticker: PTPI), a resource for investors and traders seeking the latest updates and insights on Petros Pharmaceuticals stock.
News about Petros Pharmaceuticals, Inc. (PTPI) centers on its efforts to build a technology-driven platform for prescription-to-over-the-counter (Rx-to-OTC) drug switches and its evolving capital markets profile. Company press releases describe Petros’ transition toward a smart healthcare technology model, highlighting development of a proprietary SaaS platform and Software-as-a-Medical-Device (SaMD) web application designed to help pharmaceutical sponsors navigate FDA requirements for nonprescription access.
Readers following PTPI news will see updates on the company’s AI- and big data–enabled platform, including collaborations with a big data and analytics provider and with Innolitics, which Petros identifies as a SaMD developer. These stories discuss enhancements such as identity verification, document authentication, deep fake detection, facial and ID recognition, and machine learning–based auto capture, all intended to support safe and appropriate OTC access to formerly prescription products.
Petros’ news flow also includes regulatory and policy context, with management statements about alignment with FDA’s "Nonprescription Drug Product with an Additional Condition for Nonprescription Use" (ACNU) rules and U.S. executive orders aimed at expanding OTC access and lowering drug prices. The company frequently references the emerging self-care market and its belief that its technology-assisted platform could help pharmaceutical partners pursue Rx-to-OTC switches across multiple indications.
In addition, PTPI news covers corporate and capital markets developments such as a reverse stock split, public offerings of common stock and warrants, and changes in listing status, including suspension and delisting from Nasdaq and transition to OTC trading. Coverage also addresses the deconsolidation and discontinued operations of Metuchen Pharmaceuticals and its subsidiaries, which Petros presents as part of a broader corporate realignment and balance sheet strengthening effort. Investors and observers can use this news stream to track Petros’ technology milestones, regulatory positioning, and key corporate actions over time.
Petros Pharmaceuticals (Nasdaq: PTPI) announced the formation of a steering committee aimed at expanding access to its erectile dysfunction medication, Stendra® (avanafil), potentially moving towards Over the Counter (OTC) status. This initiative builds upon two years of efforts to enhance patient engagement. Key committee members include industry veterans experienced in Rx to OTC transitions. Stendra® generated approximately $30 million in gross revenues in 2019 and is covered for 75% of commercially insured lives. The company aims to accelerate Stendra®'s relaunch with a focused strategy.
Petros Pharmaceuticals (Nasdaq: PTPI) announces that its president and chief commercial officer, Fady Boctor, will present at NobleCon17 on January 20, 2021, at 9:00 AM ET. The presentation will be part of a virtual investor conference, free to attend for interested investors.
A video webcast will be available the following day on the company's website and on Channelchek, which will also rebroadcast the presentation next month. Petros focuses on innovative therapeutics addressing men's health issues, including erectile dysfunction and Peyronie's disease.
Synaptogenix, Inc. (OTC: SNPX) successfully spun off from Neurotrope Bioscience, focusing on neuro-restorative therapies for Alzheimer's and other neurodegenerative diseases. The lead compound, Bryostatin-1, has shown safety and cognitive improvement in clinical studies. Synaptogenix is advancing its NIH Phase 2 trial, extending dosing to six months, and exploring additional NIH grants. Management emphasizes strategic realignment to enhance shareholder value. The company is poised for growth amid rising interest in new treatment strategies for cognitive diseases.